Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link

This article was originally published in The Pink Sheet Daily

Executive Summary

But the data also suggest a higher cancer risk could be due to "patient characteristics," and not Lantus itself.

You may also be interested in...



FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet

Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.

FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet

Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.

Sanofi-Aventis Licenses CureDM's Early-Stage Diabetes Compound To Bolster Pipeline

Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel